Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Related Research units
Abstract
We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 6 |
| ISSN | 0007-0920 |
| Publication status | Published - 2012 |
| pubmed | 22892393 |
|---|
